FDA Approves Otarmeni Gene Therapy
Analysis based on 7 articles · First reported Apr 23, 2026 · Last updated Apr 24, 2026
The approval of Lunsotogene parvec by the United States — Food and Drug Administration is a significant positive for Regeneron Pharmaceuticals, as it marks a groundbreaking advancement in gene therapy for a rare disease. This event could lead to increased investor confidence in the biotechnology and pharmaceutical sectors, particularly for companies focused on rare disease treatments and gene therapies.
The United States — Food and Drug Administration has granted accelerated approval to Lunsotogene parvec, a dual adeno-associated virus (AAV) vector-based gene therapy developed by Regeneron Pharmaceuticals. This marks the first-ever gene therapy approved for the treatment of genetic hearing loss, specifically for pediatric and adult patients with severe-to-profound sensorineural hearing loss associated with biallelic variants in the OTOF gene. The approval, issued 61 days after the Biologics License Application filing, was facilitated by the Commissioner's National Priority Voucher pilot program, designed to accelerate therapies for rare diseases with unmet medical needs. Clinical trials, including the CHORD trial published in the The New England Journal of Medicine, demonstrated significant improvements in hearing for 80% of participants, with 42% achieving normal hearing levels. Prior to Lunsotogene parvec, no disease-modifying treatments existed for OTOF-related deafness. Regeneron Pharmaceuticals has committed to making Lunsotogene parvec available at no cost to eligible patients in the United States. FDA Commissioner Marty Makary highlighted the approval as a major milestone in genetic hearing loss treatment.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard